EHA 2020 – the sickle cell competition hots up
Behind Global Blood and Novartis, Bluebird leads a pack of biotechs wanting a slice of the sickle cell disease market.
UCB’s growth driver squares up against the competition
With data from a head-to-head trial against Cosentyx due soon, UCB’s bimekizumab seeks to enter a crowded psoriasis market.
Chinook marks an ignominious end for Sting
Aduro finally runs up the white flag on Sting agonism, and becomes a listed shell for Chinook Therapeutics.
US FDA approval tracker: several early decisions in May
Last month the FDA greenlit four oncology approvals early and the first GnRH antagonist in uterine fibroids.
Ibrance trial halt threatens Pfizer’s growth targets
One trial of Pfizer’s drug in early breast cancer has been stopped, and expectations dim for another.
Go or no go? A busy month ahead for US FDA decisions
June will be hectic for the US regulator, with many approval decisions due, including one for subcutaneous Arzerra in multiple sclerosis and Tazverik in follicular…
J&J holds its own on sales per employee
Johnson & Johnson is easily the largest big pharma employer, and on certain metrics outstrips smaller rivals.
Big Pharma remains bullish in the face of Covid-19
So far so good, as much of pharma shrugs off the full-year impact of Covid-19.
Remember Chantix? It’s back – for dry eye disease
The smoking-cessation drug, reformulated for nasal delivery, could be launched for dry eye, Oyster Point hopes.
